China’s in vitro diagnostics (IVD) industry is undergoing profound restructuring. As centralized volume-based procurement (VBP) becomes a regular practice nationwide, price competition has intensified, continuously squeezing profit margins across the sector. Faced with compound pressures, identifying new growth drivers has become an inevitable requirement for enterprises to survive and thrive. Going global has shifted from an optional strategy to a mandatory priority.

In July 2026, WHX Labs Bangkok grandly opened in Bangkok, Thailand, bringing together elite players from the global IVD industry. Over 12,000 professional visitors and more than 400 exhibitors from 73 countries gathered at the event. Thai Deputy Prime Minister Anutin Charnvirakul attended the opening ceremony and toured the exhibition halls, announcing that the healthcare industry will be designated a new engine of national economic growth, with full efforts to develop Thailand into ASEAN’s premier medical hub.

Deheng Medical showcased its quantum dot immunofluorescence allergen testing platform at the exhibition, engaging global industry peers to discuss the future of precise allergen diagnosis.

Competition within China’s IVD sector has grown fiercer in 2026. Centralized procurement coverage has expanded from biochemistry and immunodiagnostics to molecular diagnostics, driving continuous price declines and drastically cutting profits for traditional distribution and SPD models. While VBP has lowered product prices, it has also forced the industry to upgrade quality and operational efficiency.

As the domestic market shifts from incremental expansion to stock competition, overseas markets are no longer merely an added bonus—they are a critical pillar enabling enterprises to sustain R&D investment and maintain competitiveness. Meanwhile, emerging markets across Southeast Asia, Africa, Latin America and beyond face urgent demand for upgraded medical infrastructure, with governments strongly inclined to introduce cost-effective diagnostic products. Boasting outstanding cost-performance, Chinese IVD products are presented with dual opportunities from favorable policies and market demand for overseas expansion.

During the exhibition, Deheng Medical spotlighted its full portfolio of allergen-specific IgE testing products built on quantum dot immunofluorescence technology. ???? Empowered by Quantum Dot Technology: Nano-sized quantum dots are used to label antibodies, delivering strong and stable fluorescent signals with a detection sensitivity of 0.1 IU/mL. The panel covers 27 common allergens including total IgE (e.g., pollen, dust mites, cow’s milk). ???? Whole Blood Compatibility: No centrifugation required; fingertip blood can be tested directly, ideal for pediatric testing and emergency rapid diagnosis. ???? Convenient Ambient Temperature Storage & Transportation: Test kits remain stable for 24 months at room temperature without cold chain logistics, perfectly suited for primary medical institutions and remote clinics. ⚡ Ultra-Fast & Accurate Detection: Quantitative test reports are generated in just 15 minutes from a single drop of blood, drastically boosting testing efficiency and delivering robust support for clinical diagnosis. ???? Wide Application Scenarios: Applicable to hospital clinical departments, primary care facilities, clinics and the emerging at-home testing market. Precise quantitative results assist clinicians in evaluating allergy severity and monitoring desensitization therapy outcomes.

Southeast Asia’s tropical climate leads to a high prevalence of allergic diseases, yet local allergen testing resources remain limited. Conventional testing solutions mostly rely on imported equipment, which come with high costs and complex operation workflows. Deheng Medical fills this market gap: its system requires only trace peripheral blood, delivers drastically faster results, and maintains stable performance in high-humidity environments, making it an ideal fit for primary healthcare settings across tropical regions.

Deheng Medical’s allergen testing platform garnered enthusiastic feedback and in-depth inquiries from medical institutions and distributors across Thailand, the Philippines, Indonesia and other nations during the show. The company’s fully closed-loop technology ecosystem, spanning core raw materials to end-user test kits, provides overseas partners with a solid foundation for long-term, stable and sustainable deep cooperation.

China’s IVD industry is experiencing a profound value transformation, evolving from "Made in China" to "Led by Chinese Innovation". Fierce domestic competition serves as rigorous industry training, while supportive national policies provide external momentum. Nevertheless, the true benchmark of an enterprise’s standing lies in the depth of its technological innovation and precision of niche market focus.

Built on quantum dot immunofluorescence technology, Deheng Medical has anchored itself in the blue ocean market of precise allergen testing, carving out a distinct position within the global diagnostic industry landscape. In 2026, Deheng Medical officially accelerates its globalization strategy, starting with Southeast Asia. This expansion represents far more than geographical market coverage—it is a technological calling card presented by an innovative Chinese enterprise to the global allergen diagnostics sector. Deheng’s global growth story is now writing its resounding opening chapter.